HRGN Stock — Harvard Apparatus Regenerative Technology Inc.

Harvard Apparatus Regenerative Technology Inc. (HRGN)

Updated October 16, 2026.

HRGN is a Stock. Total return is -98.1% over the past 13 years, 542.6 points behind SPY at 444.5%.

Harvard Apparatus Regenerative Technology Inc. is a clinical-stage biotechnology company developing regenerative-medicine treatments for disorders of the gastrointestinal system and other organs affected by cancer, trauma, or birth defects, with a lead product candidate in Cellspan Esophageal Implant; the company also sells consumer health products including dietary supplements. The company does not currently have an established distribution schedule. This security may appeal to investors seeking exposure to early-stage biotechnology development with no current income component.

HRGN performance versus SPY

Price and return data through 2026-10-16.

Total return is -98.1% over the past 13 years, 542.6 points behind SPY at 444.5%. Over the past year its total return — price change plus distributions reinvested — is 22.2%. Its deepest 1-year drawdown was 55.0%.

HRGN key facts

Asset type

Stock

Asset class

Equity

Inception date

10/21/2013

Distribution frequency

None

Last close

$2.23 (as of 2026-10-16)

Market cap

$45,234,370

Average volume

500.0

Beta

-0.391

Payout ratio

0.0%

EPS

$-0.39

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

HRGN risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 55.0%.

Who may consider HRGN — and who may not

It is a weaker fit for investors who need monthly cash flow (HRGN does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on HRGN

• All tickers starting with H

Tagged: Healthcare.

Frequently asked questions